Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe Jan 23, 2019 7:30am EST
Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City Dec 05, 2018 7:30am EST
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update Nov 06, 2018 4:01pm EST
Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition Nov 01, 2018 4:01pm EDT
Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results Oct 30, 2018 7:30am EDT
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries Oct 29, 2018 8:00am EDT
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients Oct 11, 2018 7:30am EDT
